Brazil’s private healthcare consolidation is not uniform. It produces champions — and reveals distortions in value creation.
The 2025 data make that clear. Amil, SulAmérica and BradSaúde captured a disproportionate share of industry profits, supported by pricing discipline, risk selection and, crucially, financial income in a high interest-rate environment. Profitability — not scale — has become the true marker of leadership.
Hapvida, the poster child of vertical integration, sits on the other side of that divide. The company reported a net loss of R$29.1mn in the fourth quarter of 2025, with a cash medical loss ratio of 75.5% and EBITDA margin compressed to 9.0%. Revenue is still growing, but returns are not. Expansion of its own network has pushed costs up ahead of efficiency gains, while its beneficiary base has shrunk in more competitive regions.
Markets have already delivered their verdict. The shares are down nearly 80% over the past 12 months, suggesting that the loss of confidence is structural rather than cyclical. Yet the stock trades at roughly 5 times estimated 2027 earnings — a multiple that looks cheap, but may reflect uncertainty rather than opportunity.
Recent reports from JPMorgan cut earnings estimates by as much as 70% for 2026 and point to a slow margin recovery stretching into 2027–28. The issue is not purely cyclical. Better service — fewer queues, more access — has increased utilisation and therefore costs. Pricing discipline protects long-term margins but comes at the expense of near-term volumes, particularly in Brazil’s more competitive southeast.
The contrast with other models is stark. Bradesco is doubling down on focus through BradSaúde, while Rede D’Or, via SulAmérica, is tightening integration between payer and provider to capture value across the chain. In a sector where returns on equity have rebounded, there is even room for price competition — penalising those still adjusting their operating model.
Scale helps, but it does not protect. In a system shaped by medical inflation, judicialisation and intensifying competition, execution and capital discipline matter more than growth.
Consolidation still promises value. After an almost 80% share price decline, however, everything depends on execution.
Leave a Reply